LB Pharmaceuticals (LBRX) announced the appointments of William Kane and Rekha Hemrajani to its Board of Directors effective as of the pricing of its initial public offering on September 10, 2025. Kane is currently President and CEO of Uniquity Bio. Hemrajani currently serves on the boards of directors of ALX Oncology, BioAge Labs, and MaxCyte. Her previous roles include CEO of Aravive, COO and CFO of Arcus Biosciences, COO of RAPT Therapeutics, and CFO of Sagimet Biosciences.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LBRX: